Obagi Medical Products, Inc. (Nasdaq:OMPI), a leader in topical aesthetic and therapeutic skin-health systems, and Suneva Medical, Inc., a rapidly growing aesthetics company, jointly announce a partnership to co-distribute ReGenica Facial Rejuvenation Complex.
This technologically advanced product supports a more rapid improvement in the appearance of post-laser skin by fusing the promise of stem cells with the power of growth factors. It has been clinically proven to accelerate the return of healthy appearing skin after a combination ablative/nonablative laser treatment compared to a vehicle control in two separate studies published in peer-reviewed journals1,2. Obagi is extremely pleased to be co-distributing the ReGenica Facial Rejuvenation Complex, along with the Suneva sales force. It can now offer a clinically proven post-procedure solution to its physicians and their patients.
ReGenica's secret lies in its Multipotent CCM Complex (Cell Conditioned Media) developed by Dr. Gail K. Naughton, a renowned pioneer in the field of regenerative medicine. CCM is a highly potent composition of active growth factors and proteins not found in any other skincare product and developed through a revolutionary and highly proprietary scientific method. Only ReGenica contains this breakthrough, bovine serum-free, multipotent CCM in an innovative formulation optimized with the most advanced cosmeceutical skin conditioning agents.
“Obagi is delighted to offer another revolutionary skincare solution to patients. The addition of the ReGenica line solidifies already existing evidence that Obagi is dedicated to delivering the most efficacious, innovative products to patients seeking real solutions,” Al Hummel, Obagi’s President and CEO, said. “The Facial Rejuvenation Complex addresses the need for post-procedure skincare treatments that are not only gentle and safe for compromised skin, but also accelerate the visible improvement in the appearance of side effects associated with procedures.”
“Obagi has significant expertise and a proven track record of marketing physician-dispensed products. We believe this relationship will accelerate our penetration in the marketplace and bring ReGenica Facial Rejuvenation Complex to more physicians in need of a cutting edge post-procedure solution and are excited to have a company as successful as Obagi as our partner,” commented Nicholas Teti, Chairman and Chief Executive Officer of Suneva Medical.
The ReGenica Facial Rejuvenation Complex is available for purchase in dermatology, plastic surgery and other aesthetic physicians’ practices.
About Obagi Medical Products, Inc.
Obagi Medical Products is a specialty pharmaceutical company that develops, markets and sells, and is a leading provider of, proprietary topical aesthetic and therapeutic prescription-strength skin care systems in the physician-dispensed market. Using its Penetrating Therapeutics™ technologies, Obagi Medical's products are designed to improve penetration of agents across the skin barrier for common and visible skin conditions in adult skin including premature aging, photodamage, hyperpigmentation (irregular or patchy discoloration of the skin), acne, sun damage, rosacea, and soft tissue deficits, such as fine lines and wrinkles. Obagi Medical’s portfolio, which includes cosmetic, over-the-counter and prescription products, including 4% hydroquinone, is sold and promoted only through physician offices and requires education by a physician on proper use. The history of Obagi's skin care product introductions is as follows: Obagi Nu-Derm®, Obagi-C® Rx (a prescription-strength vitamin C and hydroquinone system), Obagi® Professional-C (a line of highly stable vitamin C serums), Obagi Condition & Enhance® for use with cosmetic procedures to enhance patient outcomes and satisfaction, ObagiELASTIderm® Eye Products and ObagiCLENZIderm® M.D. acne therapeutic systems, a formulation of ObagiCLENZIderm M.D. Systems for normal to dry skin, and ObagiELASTIderm Décolletage System, ObagiRosaclear® System, ObagiELASTILash® Eyelash Solution, Obagi Blue Peel RADIANCE®, Nu-Derm® Sun Shield SPF 50 and Obagi Hydrate™. Visit www.obagi.com for information.
Penetrating Therapeutics and Obagi Hydrate are trademarks, and Obagi, the Obagi logo, Blue Peel RADIANCE, Condition & Enhance, ELASTIderm, ELASTILash, Nu-Derm, Obagi-C, ObagiCLENZIderm and Rosaclear are registered trademarks, of Obagi Medical Products, Inc. and/or its affiliates in the United States and certain other countries.
About Suneva Medical, Inc.
Suneva Medical, Inc. is a privately held aesthetics company focused on developing, manufacturing and commercializing novel, differentiated products for the dermatology and the plastic and cosmetic surgery markets. The Company currently markets Artefill®, Refissa® and ReGenica™ Skincare in the U.S. and Bellafill™ in Canada. For more information visit www.sunevamedical.com.
1 Kellar et al. Hypoxic Conditioned Culture Medium From Fibroblasts Under Embryonic-Like Conditions Supports Healing Following Post-Laser Resurfacing. Journal of Cosmetic Dermatology, 8; 190-196; 2009.
2 Zimber et al. Human Cell-Conditioned Media Produced Under Embryonic-Like Conditions Result in Improved Healing Time After Laser Resurfacing. Aesthetic Plastic Surgery, July 2011.
ReGenica® is a trademark of Histogen, Inc., exclusively licensed to Suneva Medical, Inc.Business Wire
Last updated on: 30/01/2013
PharmiWeb.com is Europe's leading industry-sponsored portal for the Pharmaceutical sector, providing the latest jobs, news, features and events listings.
The information provided on PharmiWeb.com is designed to support, not replace, the relationship that exists between a patient/site visitor and his/her physician.